Nov 3, 2001|
MNC Pharma: Losing out to locals
The gap between the domestic pharma companies and the MNCís seems to be widening with each quarterly scorecard. Reflecting this, while market capitalisation of MNC companies has taken a severe beating in last 18-24 months, on the other hand, domestic pharma companies have generated super normal returns for investors.
Let us consider the latest financial results to analyse this further.
Domestic pharma companiesí performance summary
Defying slowdown in the domestic pharma market, net sales of top 5 pharma companies leapfrogged more than 35% while operating margins improved by 780 basis points. Both sales and operating margins jumped on the back of higher contribution from export sales.
Within exports too, companies are shifting focus from low margin bulk exports to specialty formulations. Exports contributed more than 40% of top 5 companies total revenues.
MNC companiesí performance summary
|Aventis Pharma (Hoechst)
Multinationals on the other hand registered a marginal 1.3% rise in sales, far below the industry average. Operating margins improved marginally by 120 basis points mainly on the back of restructuring exercise undertaken by almost all the pharma companies. The restructuring exercise was in the form of discontinuing of unviable brands/divisions, shifting manufacturing locations to low cost areas, product extensions and specific relaxation in DPCO. The dismal topline performance of MNCís was obviously due to continued lack of new product introductions. Consider this, while Sun Pharma launched more than 25 new products in last one quarter, Novartis launched just 4 new products in last one year.
The multinationals seem quite content in postponing the launch of their blockbuster products in India till the product patent becomes a reality. They would rather compromise revenues from Indian operations than to allow their products getting copied. The scenario for MNCís post 2005 is anybodyís guess, but in the meantime overall performance of MNC pharma companies at best would be line in with domestic industry growth which in itself is not exciting. On the other hand, Indian companies are laughing all the way to the bank on the back of huge export generic opportunities opening up.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407